Core Insights - Adaptive Biotechnologies Corporation is participating in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York, highlighting its ongoing engagement with the investment community [1][2]. Company Overview - Adaptive Biotechnologies is a commercial-stage biotechnology company focused on leveraging the adaptive immune system for disease diagnosis and treatment. The company aims to decode the adaptive immune system's genetics to enhance medical capabilities [3]. - The company operates two business segments: Minimal Residual Disease (MRD) and Immune Medicine, developing clinical diagnostics and therapeutic products for diseases such as cancer and autoimmune disorders [3]. Upcoming Events - Management is scheduled for a fireside chat on September 10 at 10:05 a.m. Pacific Time, with a live and archived webcast available on the company's website [2].

Core Insights - Adaptive Biotechnologies Corporation will report its financial results for Q1 2025 on May 1, 2025, after market close, with a conference call scheduled for 1:30 p.m. Pacific Time [1] - The company focuses on translating the genetics of the adaptive immune system into clinical products for disease diagnosis and treatment [3] Company Overview - Adaptive Biotechnologies is a commercial-stage biotechnology company that aims to leverage the adaptive immune system for disease diagnosis and treatment [3] - The company utilizes a proprietary immune medicine platform to decode the genetics of the adaptive immune system, enabling partnerships with biopharmaceutical companies and the development of clinical diagnostics [3] - The business segments include Minimal Residual Disease (MRD) and Immune Medicine, targeting diseases such as cancer and autoimmune disorders [3] Investor Relations - For investor inquiries, the Vice President of Investor Relations and FP&A is Karina Calzadilla, reachable at 201-396-1687 [4] - Media inquiries can be directed to Erica Jones, Associate Director of Corporate Communications, at 845-344-7542 [4]